Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ISRCTN89448306) titled 'Investigating infection risk and the microbiome in blood cancer patients treated with CD19 CAR-T therapy' on May 8.
Study Type: Observational
Study Design:
Longitudinal study
Primary Sponsor: University of Cambridge
Condition:
Adult patients with high-grade B-cell lymphoma undergoing treatment with CD19 chimeric antigen receptor (CAR) T-cells.
Cancer
Intervention:
This multi-centre observational study has two components: (1) prospective recruitment of a cohort of patients with high grade B-cell lymphoma undergoing CD19 CAR-T therapy for sampling and longitudinal follow-up
(2) retrospective data collection on...